PDS Biotechnology Corp: current assets
Current assets for PDS Biotechnology Corp. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PDS Biotechnology Corp financial histories
What this measure means
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
Exact concept: us-gaap:AssetsCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 28,254,085 | USD | 2026-03-30 | 10-K · 0001140361-26-012030 |
| At date | 2024-12-31 | 45,054,443 | USD | 2026-03-30 | 10-K · 0001140361-26-012030 |
| At date | 2023-12-31 | 59,055,075 | USD | 2025-03-27 | 10-K · 0001140361-25-010717 |
| At date | 2022-12-31 | 76,480,390 | USD | 2024-03-28 | 10-K · 0001140361-24-016265 |
| At date | 2021-12-31 | 66,840,191 | USD | 2023-03-28 | 10-K · 0001140361-23-014279 |
| At date | 2020-12-31 | 30,337,230 | USD | 2022-03-31 | 10-K · 0001140361-22-012244 |
| At date | 2019-12-31 | 14,470,201 | USD | 2021-03-18 | 10-K · 0001140361-21-009142 |
| At date | 2018-12-31 | 122,123 | USD | 2020-03-27 | 10-K · 0001140361-20-007252 |
| At date | 2017-12-31 | 89,054,327 | USD | 2019-02-21 | 10-K · 0001140361-19-003636 |
| At date | 2016-12-31 | 107,353,500 | USD | 2018-03-01 | 10-K · 0001140361-18-011218 |
| At date | 2015-12-31 | 131,270,505 | USD | 2017-03-02 | 10-K · 0001140361-17-010287 |
| At date | 2014-12-31 | 15,347,349 | USD | 2016-03-08 | 10-K · 0001140361-16-056994 |
Related financial histories
- PDS Biotechnology Corp: total assets
- PDS Biotechnology Corp: total liabilities
- PDS Biotechnology Corp: stockholders equity
- PDS Biotechnology Corp: cash and cash equivalents
- PDS Biotechnology Corp: net income or loss
- PDS Biotechnology Corp: operating cash flow
- PDS Biotechnology Corp: capital expenditure payments
- PDS Biotechnology Corp: financing cash flow
- PDS Biotechnology Corp: investing cash flow
- PDS Biotechnology Corp: retained earnings or deficit
- PDS Biotechnology Corp: basic weighted-average shares
- PDS Biotechnology Corp: diluted weighted-average shares
- PDS Biotechnology Corp: basic earnings per share
- PDS Biotechnology Corp: diluted earnings per share
- PDS Biotechnology Corp: income tax expense or benefit
- PDS Biotechnology Corp: net property, plant and equipment
- PDS Biotechnology Corp: share-based compensation expense
- PDS Biotechnology Corp: operating income or loss
- PDS Biotechnology Corp: interest expense
- PDS Biotechnology Corp: current liabilities
- PDS Biotechnology Corp: current accounts payable
- PDS Biotechnology Corp: operating expenses
- PDS Biotechnology Corp: research and development expense
Inspect the source
- Entity
- PDS Biotechnology Corp / CIK 0001472091
- Captured
- 2026-09-20T09:07:40.584Z
- SEC response SHA-256
69e1cee7a201b49964a3008a5c2ec76eaaf5723c75824c2caf8a2c52d86edef2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001472091.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))